National Heart Foundation and High Blood Pressure Research Council of Australia Ambulatory Blood Pressure Monitoring Consensus Committee

# Ambulatory blood pressure monitoring

This article forms part of our 'Tests and results' series for 2011 which aims to provide information about common tests that general practitioners order regularly. It considers areas such as indications, what to tell the patient, what the test can and cannot tell you, and interpretation of results.

#### Keywords: ambulatory blood pressure monitoring

Ambulatory blood pressure (ABP) monitoring involves measuring blood pressure (BP) at regular intervals (usually every 20–30 minutes) over a 24 hour period while patients undergo normal daily activities, including sleep. The portable monitor is worn on a belt connected to a standard cuff on the upper arm (*Figure 1*) and uses an oscillometric technique to detect systolic, diastolic and mean BP as well as heart rate.<sup>1</sup> When complete, the device is connected to a computer that prepares a report of the 24 hour, day time, night time, and sleep and awake (if recorded) average systolic and diastolic BP and heart rate.

The accuracy of ABP monitoring has been validated in a range of patients including young, elderly, pregnant and obese subjects (provided the correct size cuff is used). Ambulatory BP monitoring is safe and is not usually associated with complications. Occasionally oedema or petechiae of the upper arm or bruising under the inflating cuff may occur. Modern ABP devices are quiet, lightweight and easy to wear, but inflation of the cuff may cause some transient discomfort, particularly in people with hypertension or when multiple readings are triggered due to errors in measurement. Ambulatory BP measurements during the night may disturb sleep; potentially requiring retesting if there are poor nocturnal BP measurements.

## What are the indications?

- Suspected white-coat hypertension (including in pregnancy)
- Suspected masked hypertension (untreated subject with normal clinic BP and elevated ABP)

- Suspected nocturnal hypertension or no night time reduction in BP (dipping)
- Hypertension despite appropriate treatment
- Patients with a high risk of future cardiovascular events (even if clinic BP is normal)
- Suspected episodic hypertension.

#### Ambulatory BP monitoring may also be useful for:

- titrating antihypertensive therapy
- borderline hypertension
- hypertension detected early in pregnancy
- suspected or confirmed sleep apnoea
- syncope or other symptoms suggesting orthostatic hypotension, where this cannot be demonstrated in the clinic.

# When is it not recommended?

There are no specific contraindications to ABP monitoring, however, it is important that this test doesn't delay commencing drug therapy in patients with severe hypertension (ie. clinic BP grade 3; defined as systolic BP ≥180 mmHg and/or diastolic BP ≥110 mmHg) as ABP can be valuable to confirm adequacy of treatment. While not a contraindication, ABP monitoring may be inaccurate in patients with irregular heart rate and arrhythmias.<sup>1</sup>

# Where does it fit in a diagnostic approach?

Ambulatory BP monitoring provides a more reliable measure of a patient's BP than isolated clinic measures and is not subject to the 'white-coat effect', which can overestimate BP, particularly in susceptible patients. While clinic measurement of BP is useful for screening, and in the management of suspected and true hypertension. Ambulatory BP and home BP measurements add considerably to the accurate diagnosis of hypertension and the provision of optimal care. Recent recommendations from expert groups such as the United Kingdom's National Institute for Health and Clinical Excellence strongly advocate wider use of ABP monitoring in the diagnosis and management of hypertension.



Figure 1. Example of ambulatory monitors (upper left), multiple cuff sizes (lower left) and when fitted to a patient (right)

Use of these images does not constitute endorsement by the National Heart Foundation of Australia, nor the High Blood Pressure Council of Australia

# What should I tell my patient?

Patients should be aware that the device will automatically inflate the cuff and measure BP periodically over a 24 hour period. They will need to book to have the monitor fitted and, as they cannot get the device wet, they should attend after bathing. A top with loose sleeves will best accommodate the cuff and a firm waistband will help support the monitor. Patients should continue with their normal daily activities, preferably including a work day rather than a rest day. They should take all their usual medications.

When the cuff starts to inflate the patient should stop moving and talking, keep the arm still and relaxed, and breathe normally. They should avoid activities that may interfere with the device such as vigorous exercise. A brief diary is important to record timing of activities, sleep, taking of medicines, posture and symptoms (eg. dizziness) that may be related to BP.

No Medicare rebate is currently available for ABP monitoring. Costs will vary with provider and need to be discussed with the patient.

#### How does the monitor work?

Ambulatory BP monitors use cuff oscillometry. The cuff is inflated until the pressure occludes flow within the brachial artery. As the pressure is released, blood begins to flow causing fluctuations (oscillations) in the arterial wall that are detected by the monitor. These oscillations increase in intensity then diminish and cease when blood is flowing normally. The monitor defines the maximal oscillations as mean arterial BP and then uses an algorithm to calculate systolic and diastolic BP. The correct cuff size is essential and in very large patients, a conical shaped cuff is necessary. Measure BP in both arms and if the SBP difference is less than 10 mmHg, use the nondominant arm. If the SBP difference is greater than 10 mmHg, use the arm with the higher pressure. If there are contraindications to measuring BP in one arm (eg. fistula or previous axillary clearance), the monitor must be fitted on the other arm. To ensure validity, when the ABP monitoring device is fitted, at least three readings should be recorded simultaneously using a calibrated sphygmomanometer connected to the ABP monitoring device by a Y connector. Average readings for ABP and sphygmomanometer should not differ by more than 5 mmHg. Ambulatory BP monitoring devices are usually programmed to take readings at set intervals; 15–30 minutes during the day and every 30-60 minutes at night, to obtain numerous measurements while limiting interference with activity or sleep.

# What do the results mean?

Measurements obtained from ABP monitoring must be interpreted carefully with reference to diary information and the timing of medicines. Reference 'normal' ABP values for nonpregnant adults are<sup>2</sup>:

• 24 hour average <115/75 mmHg (hypertension

threshold 130/80 mmHg)

- Day time (awake) <120/80 mmHg (hypertension threshold 135/85 mmHg)
- Night time (asleep) <105/65 mmHg (hypertension threshold 120/75 mmHg).

Ambulatory BP values above 'normal' and below thresholds for hypertension are considered 'high normal'. Night time (sleeping) average systolic and diastolic BP should both be at least 10% lower than day time (awake) average.<sup>1</sup> Blood pressure load (percentage of time that BP readings exceed hypertension threshold during 24 hours) should be <20%.

Blood pressure variability, maximum systolic BP and morning BP surge should also be taken into account (and targeted by treatment). Treatment targets based on ABP are lower than the targets for clinic BP readings (eg. for clinic BP of 140/90, day time ABP equivalent is 136/87<sup>2</sup>) Importantly, ABP monitoring can be effectively used to manage antihypertensive treatment.<sup>3</sup> The frequency of ABP assessment can be guided by the changes to therapy as routinely performed using clinic assessments combined with self measurements. An example of an ABP report is shown in *Figure 2*.

## What won't the results tell you?

Ambulatory BP monitoring will not provide any information relating to cardiac arrhythmias and may be inaccurate in the setting of irregular heart rate such as in atrial fibrillation. Ambulatory BP is not designed to detect postural hypotension as the measurements occur at a fixed interval and devices do not contain inclinometers that would be required to record a patient's position. However, diary information can provide positional and event data. Ambulatory BP monitoring can be used to assess whether there is high variability of BP which is often associated with orthostatic hypotension.<sup>4</sup>

# What are the next steps if the test is negative or inconclusive?

Untreated patients at low risk of cardiovascular disease with elevated clinic BP but a normal ABP (ie. day BP is <135/85 mmHg) may have 'white-coat hypertension'. This should be confirmed with a second ABP. People with white-coat hypertension are at greater risk of developing true hypertension and glucose intolerance. They



therefore need ongoing assessment of absolute cardiovascular risk and continued monitoring with clinic and home BP measurements. Repeat ABP every 1–2 years.

For patients with high cardiovascular risk or suspected masked hypertension it is appropriate to perform an initial ABP and repeat ABP monitoring in 1–2 years, even if clinic BP remains normal. Repeat ABP and/or home BP monitoring in these patients should be guided by the initial ABP profile and response to treatment.

An inconclusive test can occur if there has been insufficient valid readings (patient removes or inactivates device) or when there has been sleep disturbances which may obscure the correct assessment of night time BP.

#### **Authors**

National Heart Foundation and High Blood Pressure Research Council of Australia Ambulatory Blood Pressure Monitoring Consensus Committee: Geoffrey A Head, Monash University Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, geoff.head@bakeridi.edu.au; Barry P McGrath, Department of Medicine, Southern Health, Melbourne, Victoria; Anastasia S Mihailidou, Department of Cardiology and the Kolling Institute of Medical Research, Royal North Shore Hospital and the University of Sydney, New South Wales; Mark R Nelson, Discipline of General Practice, School of Medicine, University of Tasmania and Menzies Research Institute Tasmania; Markus P Schlaich, Neurovascular Hypertension & Kidney Disease, Baker IDI Heart and Diabetes Institute. Melbourne, Victoria; Michael Stowasser University of Queensland School of Medicine, Princess Alexandra Hospital, Brisbane, Queensland; Arduino A Mangoni, Division of Applied Medicine, University of Aberdeen, United Kingdom; Diane Cowley, University of Queensland School of Medicine, Princess Alexandra Hospital, Brisbane, Queensland; Alison Wilson, Heart Foundation, Melbourne, Victoria.

Conflict of interest: ICMJE forms completed by all authors: Geoffrey A Head works for an institution which has received a NHMRC grant related to this work. He also has stocks in Telemetry Research; Barry P McGrath is a paid board member of Boehringer-Ingelheim and Abbott Pty Ltd; Anastasia S Mihailidou, Mark R Nelson, Michael Stowasser and Diane Cowley have declared no conflict of interest. Markus P Schlaich receives paid board membership of Abbott Pty Ltd and institution grants for NHMRC project goals. He also receives payments from Abbott Pty Ltd, Servier, BI and Novartis for lectures; Arduino A Mangoni has received payment for travel, accommodation and lectures at international conferences from Pfizer and payment from NAPP Pharmaceuticals for lecturing; Alison Wilson works for the National Heart Foundation of Australia. This work was resourced internally by the National Heart Foundation using donated funds.

#### References

- 1. McGrath BP. Ambulatory blood pressure monitoring. Med J Aust 2002;176:588–92.
- Head G, Mihailidou A, Duggan K, et al. Definition of ambulatory blood pressure targets for diagnosis and treatment of hypertension in relation to clinic blood pressure: prospective cohort study. BMJ 2010;340:c1104.
- Staessen JA, Byttebier G, Buntinx F, Celis H, O'Brien ET, Fagard R. Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. A randomized controlled trial. Ambulatory Blood Pressure Monitoring and Treatment of Hypertension Investigators. JAMA 1997;278:1065–72.
- Ejaz AA, Kazory A, Heinig ME. 24-hour blood pressure monitoring in the evaluation of supine hypertension and orthostatic hypotension. J Clin Hypertens (Greenwich) 2007;9:952–5.